ERBB receptors and cancer: the complexity of targeted inhibitors - PubMed (original) (raw)
Review
doi: 10.1038/nrc1609.
Affiliations
- PMID: 15864276
- DOI: 10.1038/nrc1609
Review
ERBB receptors and cancer: the complexity of targeted inhibitors
Nancy E Hynes et al. Nat Rev Cancer. 2005 May.
Erratum in
- Nat Rev Cancer. 2005 Jul;5(7):580
Abstract
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.
Similar articles
- ErbB receptors and signaling pathways in cancer.
Hynes NE, MacDonald G. Hynes NE, et al. Curr Opin Cell Biol. 2009 Apr;21(2):177-84. doi: 10.1016/j.ceb.2008.12.010. Epub 2009 Feb 7. Curr Opin Cell Biol. 2009. PMID: 19208461 Review. - ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG, Ahmad T. Anderson NG, et al. Front Biosci. 2002 Sep 1;7:d1926-40. doi: 10.2741/A889. Front Biosci. 2002. PMID: 12161338 Review. - [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A, Rojo F, Rovira A, Albanell J. Dalmases A, et al. Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27. Med Clin (Barc). 2013. PMID: 23809407 Review. Spanish. No abstract available. - Targeting the ERBB family in cancer: couples therapy.
Tebbutt N, Pedersen MW, Johns TG. Tebbutt N, et al. Nat Rev Cancer. 2013 Sep;13(9):663-73. doi: 10.1038/nrc3559. Epub 2013 Aug 16. Nat Rev Cancer. 2013. PMID: 23949426 Review. - Mechanisms of resistance to ErbB-targeted cancer therapeutics.
Wang Q, Greene MI. Wang Q, et al. J Clin Invest. 2008 Jul;118(7):2389-92. doi: 10.1172/JCI36260. J Clin Invest. 2008. PMID: 18568082 Free PMC article.
Cited by
- Development of small molecules targeting the pseudokinase Her3.
Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM, Gray NS. Lim SM, et al. Bioorg Med Chem Lett. 2015 Aug 15;25(16):3382-9. doi: 10.1016/j.bmcl.2015.04.103. Epub 2015 May 11. Bioorg Med Chem Lett. 2015. PMID: 26094118 Free PMC article. - Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.
Yu HA, Riely GJ. Yu HA, et al. J Natl Compr Canc Netw. 2013 Feb 1;11(2):161-9. doi: 10.6004/jnccn.2013.0024. J Natl Compr Canc Netw. 2013. PMID: 23411383 Free PMC article. - Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E, Jaime-Ramirez AC, Bhave N, Carson WE 3rd. Luedke E, et al. J Immunother. 2012 Jun;35(5):367-73. doi: 10.1097/CJI.0b013e3182562d76. J Immunother. 2012. PMID: 22576341 Free PMC article. Review. - Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model.
Kersh AE, Sasaki M, Cooper LA, Kissick HT, Pollack BP. Kersh AE, et al. Front Pharmacol. 2016 Sep 26;7:327. doi: 10.3389/fphar.2016.00327. eCollection 2016. Front Pharmacol. 2016. PMID: 27729860 Free PMC article. Review. - Advances in Targeting HER3 as an Anticancer Therapy.
Jiang N, Saba NF, Chen ZG. Jiang N, et al. Chemother Res Pract. 2012;2012:817304. doi: 10.1155/2012/817304. Epub 2012 Nov 7. Chemother Res Pract. 2012. PMID: 23198146 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous